OXIS INTERNATIONAL INC Form SC 13D/A October 06, 2008

OMB APPROVAL

OMB Number: 3235-0145 Expires: February 28, 2009

Estimated average burden

hours per response

15

# **UNITED STATES**

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# **SCHEDULE 13D**

**Under The Securities Exchange Act of 1934** 

(Amendment No. 1)\*

**OXIS International, Inc.** 

(Name of Issuer)

Common Shares, par value \$0.001

(Title of Class of Securities)

691829402

(CUSIP Number)

323 Vintage Park Drive, Suite B

Foster City, CA 94404

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

#### **September 29, 2008**

#### (Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

**Note:** Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

\* The remainder of this cover page shall be filled out for a reporting person s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

## SCHEDULE 13D

## CUSIP No. 691829402

1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only)			
		rapeutics, Inc. (formerly Axonyx Inc.) te Box if a Member of a Group (See Instructions)	
(b) " 3. SEC Use Only	7		
4. Source of Funds (See Instructions)			
OO 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)			
6. Citizenship or Place of Organization			
Delaware	7.	Sole Voting Power	
NUMBER OF SHARES	8.	0 Shared Voting Power	
BENEFICIALLY			
OWNED BY  EACH	9.	0 Sole Dispositive Power	
REPORTING			
PERSON WITH	10.	0 Shared Dispositive Power	
11. Aggregate An	nount B	0 eneficially Owned by Each Reporting Person	

0
12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

0
13. Percent of Class Represented by Amount in Row (11)

0
14. Type of Reporting Person (See Instructions)

CO

Item 1. Security and Issuer.  The title of the class of equity securities to which this statement relates is the common stock, \$.001 par value per share (the Oxis Common Stock ), of Oxis International, Inc., a Delaware corporation (the Company ). The principal executive offices of the Company are located at 323 Vintage Park Drive, Suite B, Foster City, CA 94404.			
Item 2.	Identity and Background.		
(a)	TorreyPines Therapeutics, Inc. ( TorreyPines ) (formerly Axonyx Inc.)		
	(b) The business address of TorreyPines is 1085 North Torrey Pines Road, Suite 300		
La Jolla	CA 92037		
(c)	Principal Occupation: n/a		
(d	n/a		
(e)	n/a		
(f)	TorreyPines Therapeutics, Inc. is a Delaware corporation.		
Item 3. n/a	Source and Amount of Funds and Other Consideration		
Item 4. n/a	Purpose of Transaction.		
Item 5.	Interest in Securities of the Issuer.		
Item 6.	Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer		

Materials to be Filed as Exhibits.

**Item 7.** n/a

#### **SIGNATURES**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

TORREYPINES THERAPEUTICS, INC.

Date: October 1, 2008 By: /s/ Craig Johnson

Name: Craig Johnson

Title: Vice President, Finance and

Chief Financial Officer